Find Clinical Trial
The efficacy and safety of 2g strontium ranelate in the treatment of osteoporosis in men. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year.
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Rheumatology |
| Indication | Osteoporosis |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
STRONTIUM RANELATE, |
| Active Substance Code | S012911 |
| Protocol Code | CL3-12911-016 |
| EudraCT Code | 2006-004717-17 |
Documents and links
| Results summary | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
